Stock Research for SPPI

SPPI

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

SPPI Stock Chart & Research Data

The SPPI chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the SPPI chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


SPPI Due diligence Resources & Stock Charts

The SPPI stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View SPPI Detailed Price Forecast - CNN Money CNN View SPPI Detailed Summary - Google Finance
Yahoo View SPPI Detailed Summary - Yahoo! Finance Zacks View SPPI Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View SPPI Trends & Analysis - Trade-Ideas Barrons View SPPI Major Holders - Barrons
NASDAQ View SPPI Call Transcripts - NASDAQ Seeking View SPPI Breaking News & Analysis - Seeking Alpha
Spotlight View SPPI Annual Report - CompanySpotlight.com OTC Report View SPPI OTC Short Report - OTCShortReport.com
TradeKing View SPPI Fundamentals - TradeKing Charts View SPPI SEC Filings - Bar Chart
WSJ View Historical Prices for SPPI - The WSJ Morningstar View Performance/Total Return for SPPI - Morningstar
MarketWatch View the Analyst Estimates for SPPI - MarketWatch CNBC View the Earnings History for SPPI - CNBC
StockMarketWatch View the SPPI Earnings - StockMarketWatch MacroAxis View SPPI Buy or Sell Recommendations - MacroAxis
Bullish View the SPPI Bullish Patterns - American Bulls Short Pains View SPPI Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View SPPI Stock Mentions - StockTwits PennyStocks View SPPI Stock Mentions - PennyStockTweets
Twitter View SPPI Stock Mentions - Twitter Invest Hub View SPPI Investment Forum News - Investor Hub
Yahoo View SPPI Stock Mentions - Yahoo! Message Board Seeking Alpha View SPPI Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for SPPI - SECform4.com Insider Cow View Insider Transactions for SPPI - Insider Cow
CNBC View SPPI Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for SPPI - OTC Markets
Yahoo View Insider Transactions for SPPI - Yahoo! Finance NASDAQ View Institutional Holdings for SPPI - NASDAQ


Stock Charts

FinViz View SPPI Stock Insight & Charts - FinViz.com StockCharts View SPPI Investment Charts - StockCharts.com
BarChart View SPPI Stock Overview & Charts - BarChart Trading View View SPPI User Generated Charts - Trading View




Latest Financial News for SPPI


Is Spectrum Pharmaceuticals Inc (NASDAQ:SPPI) A Financially Strong Company?
Posted on Thursday September 13, 2018

Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Spectrum Pharmaceuticals Inc (NASDAQ:SPPI) with a market-capitalization of US$2.22b, rarely draw their attention. While they are lessRead More...


Spectrum Pharma Includes First-Line NSCLC in Poziotinib Study
Posted on Thursday September 13, 2018

Spectrum Pharma (SPPI) amends poziotinib study protocol to include two cohorts to evaluate it in first-line lung cancer.


Spectrum Pharmaceuticals Expands Poziotinib Clinical Trial Into First-Line Therapy and Doses First Patient
Posted on Wednesday September 12, 2018

Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that it has initiated two new cohorts for first-line, locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with EGFR or HER2 exon 20 insertion mutations in its current Phase 2 non-small cell lung cancer (NSCLC) clinical trial. Spectrum also announced that it has dosed the first patient in the expanded patient population.


A Look at Spectrum’s Financial Position in September
Posted on Friday September 07, 2018

In the second quarter, Spectrum Pharmaceuticals (SPPI) generated net revenues of $24.2 million compared to $34.3 million in Q2 2017. In the first half of the year, Spectrum Pharmaceuticals reported net revenues of $54.7 million compared to $63.4 million in H1 2017.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.